NYSE:NVO News 27 June 2025

Biotech, Pharma, and Health Breakthroughs You Missed on August 17–18, 2025

New Drug Approvals & Clinical Trial Results Mergers, Acquisitions & Partnerships (No other major M&A deals were announced during Aug 17–18, but this Lilly-Superluminal alliance highlights the continued investment in AI-driven R&D.) Regulatory & Policy Updates Public Health & Epidemiology (No major new COVID-19 variant or pandemic threat emerged over the weekend, but health officials continue to monitor familiar foes like measles, polio, and others as vaccination lapses threaten to reverse public health gains.) Scientific & Medical Breakthroughs (Additional notable research: Other studies this week reported that a simple walking gait adjustment can ease knee arthritis as much as medication,

18 August 2025

Miracle Drugs, Mega Mergers & Outbreak Alerts – Biotech & Health News Roundup (Aug 15–16, 2025)

Wegovy (semaglutide) received FDA accelerated approval to treat metabolic dysfunction-associated steatohepatitis (MASH), becoming the first GLP-1 therapy cleared for MASH in a patient population estimated at about 5% of U.S. adults, based on part 1 of an ongoing trial showing liver health improvement. Tonix Pharmaceuticals’ Tonmya, or TNX-102 SL, was approved August 15 for fibromyalgia, the first new fibromyalgia therapy in 15 years, with two Phase 3 trials showing significantly reduced daily pain versus placebo at 14 weeks and a potential peak U.S. sales of about $800 million. Pfizer’s inclacumab, a P-selectin inhibitor acquired via the 2022 $5.4 billion Global

16 August 2025

Biotechnology · Health News · Medical Innovations · Mergers & Acquisitions · NASDAQ:BNTX · NASDAQ:CVAC · NASDAQ:TNXP · NYSE:LLY · NYSE:NVO · NYSE:PFE · Pharmaceuticals

Cures, Cash & Controversy: Global Biotech & Health Roundup (Aug 14–15, 2025)

Breakthroughs in Biotech & Pharma Big Deals & Industry Moves Regulatory & Health Policy Updates Public Health Developments Noteworthy Medical Research Healthcare Technology & Innovation Sources: Original news reports, press releases and scientific publications from Aug 14–15, 2025 fda.gov fiercebiotech.com fiercepharma.com paho.org fiercebiotech.com, as cited above. Each development is attributed to reputable sources including FDA announcements, company press statements, peer-reviewed journals, and expert commentary to ensure accuracy and context.

15 August 2025

Biotech · Controversy · Global News · Health · Innovation · NASDAQ:PGEN · NASDAQ:PRLD · NYSE:NVO

All the Breakthroughs You Missed: The Biggest Science Stories from August 10–11, 2025

Medicine & Health Space & Astronomy Climate & Environment Physics & Materials Science Technology & Innovation Sources: The above summaries are based on reports and press releases from reputable outlets and journals, including The Guardian theguardian.com theguardian.com, Science sciencedaily.com sciencedaily.com, NASA space.com, ScienceDaily/RAS sciencedaily.com sciencedaily.com, Euronews (AP) euronews.com euronews.com, Reuters reuters.com reuters.com, Nature sciencedaily.com sciencedaily.com, and university press releases sciencedaily.com sciencedaily.com. Each story’s details and quotes are drawn from the original research publications or official statements by experts involved.

11 August 2025

Breakthroughs · Discoveries · News · NYSE:NVO · Research · Science

Digital Health & Telemedicine Industry Update (June–July 2025)

In early June 2025, DispatchHealth and Medically Home completed a merger, forming one of the nation’s largest high-acuity hospital-at-home providers and operating under the DispatchHealth brand, integrating Medically Home’s virtual care technology and 24/7 clinical command centers. Teladoc Health signaled a growth and acquisitions pivot under CEO Chuck Divita, after two 2025 deals—Catapult Health (February) and UpLift (May)—to bolster chronic care management and insurance-billed virtual therapy. Novo Nordisk terminated its Wegovy distribution deal with Hims & Hers Health in late June 2025 over concerns about unregulated compounded semaglutide, sending Hims & Hers’ stock down about 30%. HerMD launched Virtual Care

3 July 2025

Digital Health · eHealth · Healthcare Technology · Industry Update · NASDAQ:MSFT · NYSE:HIMS · NYSE:NVO · NYSE:TDOC · Telemedicine

The State of Artificial Intelligence in 2025: Breakthroughs, Challenges, and the Road Ahead / Updated: 2025, July 1st, 12:02 CET

Meta launched Meta Superintelligence Labs (MSL), led by Alexandr Wang and Nat Friedman, unifying all AI R&D to accelerate AGI with a multi-billion-dollar investment reportedly over $70 billion and recruiting top talent from OpenAI, Anthropic, and Google. Microsoft unveiled the AI Diagnostic Orchestrator (MAI-DxO), powered by OpenAI’s o3 model and others, achieving 80–85.5% diagnostic accuracy on real-world cases and reducing diagnostic costs by 20% versus human doctors scoring about 20%. Apple is exploring partnerships with OpenAI, Anthropic, and Google Gemini to power the next generation of Siri, with an internal Siri LLM and a full upgrade potentially delayed until 2026.

1 July 2025

Artificial Intelligence · Future Predictions · Industry Insights · Innovation · NASDAQ:AAPL · NASDAQ:AMZN · NASDAQ:GOOGL · NASDAQ:GTLB · NASDAQ:META · NASDAQ:MSFT · NASDAQ:NVDA · NYSE:NVO · Technology Trends

Top Biotechnology and Health Tech Trends in 2025: Mid-Year Update and Forecast (Updated: June 27th, 2025)

Late 2024, the first FDA-approved CRISPR-based therapy exagamglogene autotemcel (Casgevy) reached patients, with Vertex reporting $2 million in revenue from this sickle-cell gene-editing therapy in Q3 2024. Prime Medicine’s PM359 autologous CRISPR prime-edited cell therapy for chronic granulomatous disease began a Phase I/II study in 2024, with initial first-in-human data expected in late 2025. Wave Life Sciences’ RNA base-editing drug WVE-006 showed proof-of-mechanism in humans in 2024, and multi-dose trial data are anticipated in 2025. In April 2025, the FDA approved Abeona Therapeutics’ Zevaskyn, the first cell-based gene therapy for the rare skin disorder RDEB, with launch planned in Q3

27 June 2025

2025 Trends · Biotechnology · Forecast · Health Tech · Medical Innovation · NASDAQ:ABEO · NASDAQ:ITCI · NASDAQ:PRME · NASDAQ:RARE · NASDAQ:RGLS · NASDAQ:SWTX · NASDAQ:VRTX · NASDAQ:WVE · NYSE:AZN · NYSE:CTLT · NYSE:JNJ · NYSE:NVO · NYSE:NVS

NYSE:NVO News 27 June 2025 - 18 August 2025